Zentiva to acquire APONTIS PHARMA for €85m.

Zentiva, a pharmaceutical company developing, manufacturing and marketing a wide range of generic and OTC products, agreed to acquire APONTIS PHARMA, a German pharmaceutical company specializing in Single Pill combinations, for €85m. “We are delighted that the Executive Board and the Supervisory Board of APONTIS PHARMA welcome the Offer as a long-term solution for the company. We firmly believe that under a unified ownership structure, APONTIS PHARMA will be able to provide high-quality and affordable products to even more customers across Europe, while this partnership is an important step towards achieving Zentiva’s long-term strategy and goals,” Steffen Saltofte, Zentiva CEO.